top of page

Daily Updates
Daily biotech and biopharma stock updates including recent catalyst readouts, financial news, and upcoming catalyst events.


Biopharma Daily Stock Updates - 04/21/22
$XBI $81.16 | -4.3% Covid Updates $NRXP -13.2% NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI®...
Apr 21, 2022


Biopharma Daily Stock Updates - 04/20/22
$XBI $84.79 | +0.22% Covid Updates $AZN +0.8% Evusheld significantly protected against symptomatic COVID-19 for at least six months in...
Apr 20, 2022


Biopharma Daily Stock Updates - 04/19/22
$XBI $84.60 | +1.21% Covid Updates $MRNA -1.3% Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform. source $NVAX...
Apr 19, 2022


Biopharma Daily Stock Updates - 04/18/22
$XBI $83.59 | -4.76% Covid Updates $OCGN -5.8% Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North...
Apr 18, 2022


Biopharma Daily Stock Updates - 04/15/22
$XBI $87.77 Pipeline Updates $TGTX TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and...
Apr 15, 2022


Biopharma Daily Stock Updates - 04/14/22
$XBI $87.77 | -2.92% Covid Updates $PFE 0,0% & -2.3% BNTX Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following...
Apr 14, 2022


Biopharma Daily Stock Updates - 04/13/22
$XBI $90.41 | +3.8% Covid Updates $NVAX +7.0% Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine. source...
Apr 13, 2022


Biopharma Daily Stock Updates - 04/12/22
$XBI $87.15 | -.019% Covid Updates $ Pipeline Updates $TPTX +0.6% Turning Point Therapeutics Announces Positive Topline Data by Blinded...
Apr 12, 2022


Biopharma Daily Stock Updates - 04/11/22
$XBI $87.32 | -3.34% Covid Updates $ Pipeline Updates $AGLE -6.5% Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3...
Apr 11, 2022


Biopharma Daily Stock Updates - 04/08/22
$XBI $90.34 | +-2.3% Covid Updates $NVAX +1.9% Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax'...
Apr 8, 2022


Biopharma Daily Stock Updates - 04/07/22
$XBI $92.43 | -0.96% Covid Updates $ Pipeline Updates $MNOV +3.9% MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166...
Apr 7, 2022


Biopharma Daily Stock Updates - 04/06/22
$XBI $93.33 | +0.086% Covid Updates $ Pipeline Updates $SPRO -4.1% Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data...
Apr 6, 2022


Biopharma Daily Stock Updates - 04/05/22
$XBI $93.25 | -2.96% Covid Updates $TNXP -4.9% Tonix Pharmaceuticals Announces Extension of Sponsored Research Agreement with Kansas...
Apr 5, 2022


Biopharma Daily Stock Updates - 04/04/22
$XBI $96.09 | +3.0% Covid Updates $ALGS +4.0% Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral...
Apr 4, 2022


Biopharma Daily Stock Updates - 04/01/22
$XBI $93.26 | +3.76% Pipeline Updates $CYTK Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of...
Apr 2, 2022


Biopharma Daily Stock Updates - 03/31/22
$XBI $89.88 | -0.88% Covid Updates $SRNE -1.7% Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib...
Mar 31, 2022


Biopharma Daily Stock Updates - 03/30/22
$XBI $90.68 | -3.07% Covid Updates $CYDY +0.8% CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19...
Mar 30, 2022


Biopharma Daily Stock Updates - 03/29/22
$XBI $93.55 | +4.28% Covid Updates $BNTX +3.6% & $PFE -1.0% Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for...
Mar 29, 2022


Biopharma Daily Stock Updates - 03/28/22
$XBI $89.71 | +0.1% Covid Updates $ Pipeline Updates $NBIX -0.1% Neurocrine Biosciences Announces Regulatory Approval of Dysval®...
Mar 28, 2022


Biopharma Daily Stock Updates - 03/25/22
$XBI $89.62 | -2.34% Covid Updates $VIR US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to...
Mar 26, 2022
Jump start your biotech due diligence
Our platform helps you uncover your next biotech investment opportunity
bottom of page
